Nivolumab plus ipilimumab in advanced melanoma
10.1056/nejmoa1302369 · doi-reference
Breakthrough of the year 2013. Cancer immunotherapy
10.1126/science.342.6165.1432 · doi-reference
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
10.1056/nejmoa1200690 · doi-reference
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells
10.1126/scitranslmed.3003761 · doi-reference
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
10.1056/nejmoa1200694 · doi-reference
Enhancement of antitumor immunity by CTLA-4 blockade
10.1126/science.271.5256.1734 · doi-reference
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
10.1200/jco.2007.14.8288 · doi-reference
Hypoxia and the extracellular matrix: drivers of tumour metastasis
10.1038/nrc3726 · doi-reference
Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells
10.1002/hep.24108 · doi-reference
Regulation of cancer cell metabolism
10.1038/nrc2981 · doi-reference
Microenvironmental regulation of metastasis
10.1038/nrc2618 · doi-reference
Hepatocellular carcinoma pathogenesis: from genes to environment
10.1038/nrc1934 · doi-reference
Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring
10.1007/s13277-013-1141-0 · doi-reference
MicroRNAs as therapeutic strategy for hepatitis B virus-associated hepatocellular carcinoma: current status and future prospects
10.3748/wjg.v20.i20.5973 · doi-reference
MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target
10.1155/2014/486407 · doi-reference
Roles of microRNAs in the hepatitis B virus infection and related diseases
10.3390/v5112690 · doi-reference
MicroRNAs in the tumour microenvironment: big role for small players
10.1530/erc-13-0119 · doi-reference
Microenvironmental regulation of cancer metastasis by miRNAs
10.1016/j.tcb.2013.09.007 · doi-reference
Role of hepatitis B surface antigen in the development of hepatocellular carcinoma: regulation of lymphoid enhancer-binding factor 1
10.1186/1756-9966-28-58 · doi-reference
Hepatitis B virus X protein stimulates the Hedgehog-Gli activation through protein stabilization and nuclear localization of Gli1 in liver cancer cells
10.1016/j.canlet.2011.05.033 · doi-reference
Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signaling
10.1016/j.canlet.2010.09.018 · doi-reference
Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B
10.1002/hep.22765 · doi-reference
Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells
10.1002/hep.25899 · doi-reference
Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma
10.1371/journal.pone.0041931 · doi-reference
Hepatitis B virus X antigen promotes transforming growth factor-beta1 (TGF-beta1) activity by up-regulation of TGF-beta1 and down-regulation of alpha2-macroglobulin
10.1099/vir.0.19650-0 · doi-reference
The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4
10.1038/sj.onc.1201760 · doi-reference
Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma
10.1038/labinvest.2010.147 · doi-reference
Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin
10.1245/s10434-011-1946-2 · doi-reference
Identification of osteopontin as a novel marker for early hepatocellular carcinoma
10.1002/hep.24703 · doi-reference
The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma
10.1007/s00432-009-0629-x · doi-reference
Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection
10.1111/j.1742-1241.2007.01368.x · doi-reference
Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma
10.1016/j.dld.2006.10.015 · doi-reference
Differential promoter usage for insulin-like growth factor-II gene in Chinese hepatocellular carcinoma with hepatitis B virus infection
10.1016/j.cdp.2005.12.004 · doi-reference
Different in situ expression of insulin-like growth factor type II in hepatocellular carcinoma: an in situ hybridization and immunohistochemical study
10.1097/00019606-199403010-00010 · doi-reference
Expression of insulin-like growth factor II (IGF-II) in human hepatocellular carcinomas: an immunohistochemical study
10.1111/j.1440-1827.1994.tb01697.x · doi-reference
Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study
10.1007/s10585-009-9283-6 · doi-reference
[Expression of vascular endothelial growth factor (VEGF) family members and prognosis after hepatic resection in HBV-related hepatocellular carcinoma]
10.3350/kjhep.2008.14.2.185 · doi-reference
Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro
10.1111/j.1365-2249.2006.03281.x · doi-reference
Hepatitis B virus X protein induced expression of interleukin 18 (IL-18): a potential mechanism for liver injury caused by hepatitis B virus (HBV) infection
10.1016/s0168-8278(02)00181-2 · doi-reference
Dual effects of interleukin-18: inhibiting hepatitis B virus replication in HepG2.2.15 cells and promoting hepatoma cells metastasis
10.1152/ajpgi.00058.2011 · doi-reference
